跳至主要内容
临床试验/ISRCTN93280043
ISRCTN93280043已完成不适用

A randomised controlled trial to evaluate whether a short course of once weekly risedronate prevents bone loss following high-dose steroid therapy for an acute exacerbation of inflammatory bowel disease

niversity Hospitals Bristol NHS Foundation Trust (UK)0 个研究点目标入组 100 人开始时间: 2008年11月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged greater than or equal to 16 years, either sex
  • 2. Ulcerative colitis and Crohn's disease
  • 3. Experiencing a relapse
  • 4. Requiring steroid therapy

排除标准

  • 1. Aged under 16 years
  • 2. Use of corticosteroids in the preceding 3 months
  • 3. Evidence of osteoporosis (known vertebral fracture, T score less than -2.5)
  • 4. Pregnant and lactating women
  • 5. Women of childbearing age will be eligible provided they use reliable contraception
  • 6. Bone active therapy within previous 12 months (excluding calcium and low dose vitamin D)
  • 7. Previous treatment with a bisphosphonate at any time
  • 8. Associated disorder which may influence bone metabolism
  • 9. Lactose intolerance

研究者

发起方
niversity Hospitals Bristol NHS Foundation Trust (UK)

相似试验